Skip to main content
Premium Trial:

Request an Annual Quote

Microlin Cuts IPO Target Price Range Again


NEW YORK (GenomeWeb) – Just days after cutting the proposed price range for its stock in a planned initial public offering, Microlin Bio has once again slashed the proposed offering price for its shares by $2 to between $4.50 and $5.50.

As reported by Gene Silencing News, the company first filed to go public on the Nasdaq in February, disclosing that it hoped to get between $6 to $8 a share for 3.6 million shares total. A few months later, it raised that range to $10 to $12, with the goal of floating 2.7 million shares.

Then, last week, it said in a filing with the US Securities and Exchange Commission that it would look to sell 4.3 million shares for between $6.50 and $7.50 apiece. Assuming a $7 per share IPO price and the 8.4 million shares outstanding following the transaction, this would have given Microlin a market capitalization of about $59 million.

The company is now hoping to sell 6.9 million shares. Assuming it closes its IPO at the mid-range price of $5 per share, which would result in roughly 10.2 million shares outstanding, the firm's market cap would be $51 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.